Huimin Wang - 15 Jun 2021 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role: CVP, Japan & Intercontinental
Signature: Linda J. Park, Attorney-in-Fact
Issuer symbol: EW
Transactions as of: 15 Jun 2021
Net transactions value: -$503,194
Form type: 4
Filing time: 15 Jun 2021, 20:33:03 UTC
Previous filing: 19 May 2021
Next filing: 08 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EW	Common Stock	Options Exercise	$138,176	+6,350	+6.5%	$21.76	104,240	15 Jun 2021	Direct	F1
transaction	EW	Common Stock	Sale	$641,370	-6,350	-6.1%	$101.00	97,890	15 Jun 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EW	Employee Stock Option (Right to Acquire)	Options Exercise	$0	-6,350	-11%	$0.000000	50,800	15 Jun 2021	Common Stock	6,350	$21.76	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 4, 2021.
F2	This transaction was executed in multiple trades at prices ranging from $100.7150 to $101.1900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.